Total revenue (before excise duties) of $12.9 million in Q1 2021, represents over 7% favourability over the $12.0 million Q1 2021 guidance previously provided
Net revenue of $10.3 million in Q1 2021, represents a 102% sequential increase over Q4 2020, reflecting record sales of higher-margin, direct-to-consumer, and direct-to-patient products
Reports significant improvement in SG&A expenses, down 66% from previous quarter
Gross Profit Before Fair Value Changes improved over $22 million sequentially from Q4 2020
Adjusted EBITDA sequential improvement of over $31 million versus Q4 2020, reflecting improved gross profit and reduced expenses resulting from optimization initiatives
20% of life is what happens to you and 80% is how you react to what happens to you...